Schonfeld Strategic Advisors LLC Paratek Pharmaceuticals, Inc. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.37 - $2.54 $10,960 - $20,320	-8,000 Reduced 36.53%	13,900 $35,000
Q4 2022 Feb 14, 2023	SELL	$1.67 - $2.51 $32,398 - $48,693	-19,400 Reduced 46.97%	21,900 $40,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $2.93 $49,392 - $73,836	25,200 Added 156.52%	41,300 $106,000
Q2 2022 Aug 15, 2022	SELL	$1.73 - $3.09 $265,901 - $474,933	-153,700 Reduced 90.52%	16,100 $31,000
Q1 2022 May 16, 2022	BUY	$2.94 - $4.77 $499,212 - $809,945	169,800 New	169,800 $504,000
Q4 2018 Feb 14, 2019	SELL	$4.8 - $11.6 $408,000 - $986,000	-85,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$9.05 - $10.95 $905 - $1,095	-100 Reduced 0.12%	85,000 $825,000
Q2 2018 Aug 14, 2018	BUY	$10.2 - $13.9 $103,020 - $140,390	10,100 Added 13.47%	85,100 $868,000
Q1 2018 May 15, 2018	SELL	$12.65 - $18.85 $348,811 - $519,769	-27,574 Reduced 26.88%	75,000 $975,000
Q4 2017 Feb 14, 2018	SELL	$17.45 - $25.6 $371,929 - $545,638	-21,314 Reduced 17.2%	102,574 $1.84 Million
Q3 2017 Nov 14, 2017	BUY	$18.9 - $28.2 $2.34 Million - $3.49 Million	123,888	123,888 $3.11 Million

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.